Once-Daily MMX Mesalamine in the Management of Ulcerative colitis
Clinical Medicine. Gastroenterology · 2011
DOI: 10.4137/cgast.s4276 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Medicine. Gastroenterology, 2011. Verfasst von Wojciech Blonski und 2 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Mesalamine (5-ASA) has been the mainstay therapy of mild to moderate active ulcerative colitis both as an induction and maintenance treatment. Multimatrix system (MMX) 5-ASA is a recently developed formulation of 5-ASA allowing for slow and gradual release of 5-ASA throughout the entire colon. This review article discusses the structure, pharmacokinetics, efficacy and safety of this new 5-ASA formulation.
Zitieren
APA
Blonski, W., Buchner, A. M., & Lichtenstein, G. R. (2011). Once-Daily MMX Mesalamine in the Management of Ulcerative colitis. Clinical Medicine. Gastroenterology. https://doi.org/10.4137/cgast.s4276
Vancouver
Blonski W, Buchner AM, Lichtenstein GR. Once-Daily MMX Mesalamine in the Management of Ulcerative colitis. Clinical Medicine. Gastroenterology. 2011. doi:10.4137/cgast.s4276
BibTeX
@article{Blonski2011,
author = {Blonski, Wojciech and Buchner, Anna M. and Lichtenstein, Gary R.},
title = {Once-Daily MMX Mesalamine in the Management of Ulcerative colitis},
journal = {Clinical Medicine. Gastroenterology},
year = {2011},
doi = {10.4137/cgast.s4276}
}
EUVIMED